News

iTHRIV Announces Health Research Pilot Project Recipients

The Clinical and Translational Science Award (CTSA) hub partnership between Virginia Tech, the University of Virginia, Carilion Clinic, and Inova Health System has awarded $200,000 in funding to five research projects through the Pilot Translational and Clinical Studies Program. Multi-institutional teams of scientists, physicians, and engineers will study Parkinson’s disease, celiac disease, pediatric heart transplant, pediatric telemedicine, and epilepsy.

Locally, the CTSA partners administer the grants through the integrated Translational Health Research Institute of Virginia (iTHRIV). iTHRIV is funded by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, through award number UL1TR003015.

The awarded pilot projects include:

Studying auditory therapy for Parkinson’s disease

Della Williams, a neurologist at Carilion Clinic and an assistant professor of internal medicine at the Virginia Tech Carilion School of Medicine, and Sujith Vijayan, an assistant professor in the Virginia Tech College of Science’s School of Neuroscience, are studying if patients with Parkinson’s disease can benefit from background noise during sleep.

Designing an interactive training system for pediatric telemedicine cart operations incorporating augmented reality

Elham Morshedzadeh, an assistant professor of industrial design in Virginia Tech’s College of Architecture and Urban Studies; Andre Muelenaer, a professor of practice in Virginia Tech’s College of Engineering, a professor of pediatrics for the Virginia Tech Carilion School of Medicine, and a pediatric pulmonologist at Carilion; Wallace Lages, an assistant professor in the School of Visual Arts; and Melinda Schriver, Carilion’s director of digital health, are designing a robust and affordable training program to help improve telemedicine encounters for infants and pre-school children.

Measuring medication in patients with epilepsy

Aashit Shah, Carilion’s chief of neurology and a professor of internal medicine at the Virginia Tech Carilion School of Medicine, and Sujith Vijayan will analyze intracranial electrical signals in epilepsy patients to help identify which brain regions are affected by certain neuroactive drugs.

Searching for genetic markers for celiac disease with machine learning

Sana Syed, an assistant professor in the UVA School of Medicine’s department of pediatrics, and Suchitra Hourigan, Inova Children’s Hospital’s vice chair of research and innovation, are studying gut tissue biopsies and genetic markers from patients diagnosed with celiac disease, to assess the risk of these patients developing other diseases, including type 1 diabetes and hypothyroidism.

Defining donor characteristics for pediatric heart transplants

Heart transplantation is the standard of care for pediatric patients with end-stage heart failure or inoperable congenital defects, yet nearly 20 percent of patients with these conditions die while on the waitlist. To help increase the odds of successful pediatric heart transplants, Michael McCulloch, an associate professor and a pediatric cardiologist at UVA Children’s Hospital Heart Center, and Michael Porter, an associate professor of systems engineering in UVA’s School of Engineering and Applied Science, will anlayze donor echocardiographic data to identify which donor characteristics contribute to positive heart transplant recipient outcomes.

Recent News

01/18/2026

Gerry Brunk Joins Focused Ultrasound Foundation’s Council

The Foundation is pleased to welcome Gerry Brunk to its Council, a committed group of goodwill ambassadors who partner with the Board of Directors and staff to offer guidance, raise funds, and generate awareness for focused ultrasound technology. Mr. Brunk co-founded Lumira Ventures, a North American healthcare venture capital firm, and serves as managing director in the firm’s Boston office. He has led investments in

01/12/2026

Nanochon closes $4.1M Seed Prime II Funding Round

Nanochon, a Washington, DC-based orthopedic device company developing an implant for treating articular cartilage defects in the knee, has secured commitments to close an oversubscribed funding round, bringing its total capital raised to date to $11.3 million. The round was led by cultivate(MD), with significant contributions from The University of Virginia UVA Seed Fund, WSGR,

01/07/2026

ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. Howard Berman, Ph.D., executive chairman, stated: